

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	IDURSULFASE
PRONUNCIATION	eye dur sul' fase
THERAPEUTIC CLAIM	treatment of Hunter Syndrome (enzyme that degrades the glycosaminoglycans heparan sulfate and dermatan sulfate)

CHEMICAL NAMES

- (1) sulfatase, L-idurono-
- (2) α -L-iduronate sulfate sulfatase

STRUCTURAL FORMULA

SETQANSTTD	ALNVLLIIVD	DLRPSLGCYG	DKLVRSPNID
QLASHSLLFQ	NAFAQQAVCA	PSRVSFLTGR	RPDTTRLYDF
NSYWRVHAGN	FSTIPQYFKE	NGYVTMSVGK	VFHPGISSNH
TDDSPYSWSF	PPYHPSSEKY	ENTKTCRGPD	GELHANLLCP
VDVLDVPEGT	LPDKQSTEQA	IQLLEKMKTS	ASPFFLAVGY
HKPHIPFRYP	KEFQKLYPLE	NITLAPDPEV	PDGLPPVAYN
PWMDIRQRED	VQALNISVPY	GPIPVDFQRK	IRQSYFASVS
YLDTQVGRL	SALDDLQLAN	STIIAFTSDH	GWALGEHGEW
AKYSNFDVAT	HVPLIFYVPG	RTASLPEAGE	KLFPYLDPDFD
SASQLMEPGR	QSMDLVELVS	LFPTLAGLAG	LQVPPRCVPV
SFHVELCREG	KNLLKHFRFR	DLEEDPYLPG	NPRELIAYSQ
YPRPSDIPQW	NSDKPSLKDI	KIMGYSIRTI	DYRYTVWVGF
NPDEFLANFS	DIHAGELYFV	DSDPLQDHNM	YNDSQGGDLF

QLLMP

MOLECULAR FORMULA sequence)	$C_{2689}H_{4057}N_{699}O_{792}S_{14}$ (reduced peptide
--------------------------------	---

MOLECULAR WEIGHT	61,880 daltons
------------------	----------------

TRADEMARK	Unknown as yet
-----------	----------------

MANUFACTURER	Transkaryotic Therapies, Inc.
--------------	-------------------------------

CODE DESIGNATION	EC 3.1.6.13
------------------	-------------

<u>CAS</u> REGISTRY NUMBER	50936-59-9
----------------------------	------------

